5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
Blunted neuroendocrine and physiological responses to the selective 5-HT(1A) receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA). In order to examine whether this hyporesponsiveness to ipsapirone is modified by pharmacological or non-pharmacological therapeutic interventions, challenges with an oral dose of ipsapirone (0.3 mg/kg) and placebo were performed in patients with PDA before and after 10 weeks of treatment with clomipramine, aerobic exercise and placebo. Before treatment, administration of ipsapirone was followed by significant increases of cortisol, anxiety and other psychopathological symptoms in comparison to the placebo challenge. In addition, a significant decrease of body temperature was observed. After the 10-week treatment period, the psychological responses to ipsapirone were significantly reduced in the clomipramine and the exercise group. In contrast, there was a non-significant trend towards higher cortisol responses after clomipramine and exercise treatment. The hypothermic response to ipsapirone was significantly reduced by clomipramine treatment. In conclusion, our results demonstrate that effective treatment of panic disorder has divergent effects on the psychological, neuroendocrine and temperature responses to ipsapirone.
Broocks
Andreas
A
Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany. broocks.a@psychiatry.mu-luebeck.de
Meyer
T
T
Opitz
M
M
Bartmann
U
U
Hillmer-Vogel
U
U
George
A
A
Pekrun
G
G
Wedekind
D
D
Rüther
E
E
Bandelow
B
B
D000293:Adolescent; D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology; D001831:Body Temperature / Q000187:drug effects; D002997:Clomipramine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D015444:Exercise; D005080:Exercise Test; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000378:metabolism* / Q000523:psychology / Q000628:therapy*; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000097:blood / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D044263:Receptors, Serotonin, 5-HT1; D017366:Serotonin Receptor Agonists / Q000097:blood / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D002997:Clomipramine; D006854:Hydrocortisone; D011743:Pyrimidines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; C043077:ipsapirone